Skip to content
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPE
Home
update
Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPE
Post Author:
eyetem@admin
Post navigation
Previous Post
Eyestem Announces completion of Phase one of its RPE cell therapy with promising efficacy and safety outcomes
